Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Pappo

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Pediatric Blood & Cancer|June 26, 2021
Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendationsAndrea Ferrari, Ricardo Lopez Almaraz, Yves Reguerre, et al.
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
Pediatric Blood & Cancer|May 19, 2017
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupErin R Rudzinski, James R Anderson, Yueh-Yun Chi, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 StudyChristopher L Tinkle, Alberto Pappo, Jianrong Wu, et al.
Science Immunology|February 4, 2022
Antigen cross-presentation in young tumor-bearing hosts promotes CD8<sup>+</sup> T cell terminal differentiationArdiana Moustaki, Jeremy Chase Crawford, Shanta Alli, et al.
Pediatric Blood & Cancer|April 3, 2016
Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk MelanomaFariba Navid, Cynthia E Herzog, John Sandoval, et al.
Molecular Cancer Research : MCR|January 13, 2023
Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid SarcomaJennifer L Kamens, Jinjun Dang, Timothy I Shaw, et al.
Developmental Cell|April 28, 2022
The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcomaAnand G Patel, Xiang Chen, Xin Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Contribution of Germline Predisposition to Pediatric Thyroid CancerClaudia Harrison, Alise K Blake, Yin Su, et al.
The Lancet. Oncology|December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trialBirgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Pediatric Blood & Cancer|June 26, 2021
Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendationsAndrea Ferrari, Ricardo Lopez Almaraz, Yves Reguerre, et al.
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
Pediatric Blood & Cancer|May 19, 2017
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupErin R Rudzinski, James R Anderson, Yueh-Yun Chi, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 StudyChristopher L Tinkle, Alberto Pappo, Jianrong Wu, et al.
Science Immunology|February 4, 2022
Antigen cross-presentation in young tumor-bearing hosts promotes CD8<sup>+</sup> T cell terminal differentiationArdiana Moustaki, Jeremy Chase Crawford, Shanta Alli, et al.
Pediatric Blood & Cancer|April 3, 2016
Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk MelanomaFariba Navid, Cynthia E Herzog, John Sandoval, et al.
Molecular Cancer Research : MCR|January 13, 2023
Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid SarcomaJennifer L Kamens, Jinjun Dang, Timothy I Shaw, et al.
Developmental Cell|April 28, 2022
The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcomaAnand G Patel, Xiang Chen, Xin Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Contribution of Germline Predisposition to Pediatric Thyroid CancerClaudia Harrison, Alise K Blake, Yin Su, et al.
The Lancet. Oncology|December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trialBirgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Pageof 10